Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1795129 Target Snapshot

Interleukin-6 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
144Compounds
16Assays
1Approved Drugs
148.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Interleukin-6 shows approved-linked disease relevance led by immune system disease. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P05231. Start with immune system disease, then reuse UniProt P05231 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with immune system disease, then reuse UniProt P05231 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 3 linked drugs
Open source guide
Disease program
immune system disease

Interleukin-6 shows approved-linked disease relevance led by immune system disease. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with immune system disease because it currently carries approved-linked support. Linked drugs include OLOKIZUMAB, SILTUXIMAB, SIRUKUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Interleukin-6 as ChEMBL target CHEMBL1795129, mapped to UniProt P05231. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Interleukin-6
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1795129
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P05231
Interleukin-6
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Interleukin-6 is the right protein anchor across sources, using UniProt P05231 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why immune system disease is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameInterleukin-6
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP05231
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelInterleukin-6
UniProt AccessionP05231
Component TypeProtein
Sequence Length212 aa

Interleukin-6

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Interleukin-6, mapped to UniProt P05231. Sequence length is 212 aa.

Mapped IDP05231
Review nameInterleukin-6
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Interleukin-6 shows approved-linked disease relevance led by immune system disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
immune system disease
3 linked drugs · 3 direct · 3 efficacy
Linked drugOLOKIZUMAB
Linked drugSILTUXIMAB
Linked drugSIRUKUMAB
Approved-linked Approved
Castleman disease
1 linked drug · 1 direct · 1 efficacy
Linked drugSILTUXIMAB
Approved-linked Approved
Giant Lymph Node Hyperplasia
1 linked drug · 1 direct · 1 efficacy
Linked drugSILTUXIMAB
Late clinical Phase III
COVID-19
4 linked drugs · 4 direct · 4 efficacy
Linked drugCLAZAKIZUMAB
Linked drugOLOKIZUMAB
Linked drugSILTUXIMAB
Linked drugSIRUKUMAB
Late clinical Phase III
rheumatoid arthritis
4 linked drugs · 4 direct · 4 efficacy
Linked drugCLAZAKIZUMAB
Linked drugOLOKIZUMAB
Linked drugSIRUKUMAB
Linked drugZILTIVEKIMAB
Late clinical Phase III
multiple myeloma
1 linked drug · 1 direct · 1 efficacy
Linked drugSILTUXIMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with immune system disease because it currently carries approved-linked support. Linked drugs include OLOKIZUMAB, SILTUXIMAB, SIRUKUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseimmune system disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC5043.0
EC50105.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3647443 8.96 IC50 1.1 Preclinical
CHEMBL3647441 8.96 IC50 1.1 Preclinical
CHEMBL3647442 8.89 IC50 1.3 Preclinical
CHEMBL3647445 8.68 IC50 2.1 Preclinical
CHEMBL5967615 8.6 EC50 2.5 Preclinical
CHEMBL3647447 8.55 IC50 2.8 Preclinical
CHEMBL5757665 8.42 EC50 3.8 Preclinical
CHEMBL5993886 8.42 EC50 3.77 Preclinical
CHEMBL3647440 8.4 IC50 4.0 Preclinical
CHEMBL131 8.38 IC50 4.2 Approved
Distribution

pChEMBL Value Distribution

2
5.0
3
5.5
16
6.0
21
6.5
26
7.0
48
7.5
20
8.0
6
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

PREDNISOLONE
CHEMBL131
Approved 1955
Properties Compare Identifier
Assay Landscape

Assay Landscape

16
Total Assays
125
Tested Compounds
1
Assay Types
Binding — 16 assays, 125 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 10 112 7.4
cell-based format 3 4 5.6
assay format 2 8 7.4
tissue-based format 1 1 5.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine